Nifty
Sensex
:
:
9871.50
31599.76
-1.10 (-0.01%)
-26.87 (-0.08%)

Pharmaceuticals & Drugs

Rating :
21/99

BSE: 500124 | NSE: DRREDDY

2370.75
-46.50 (-1.92%)
26-Sep-2017 | 3:58PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 2414.00
  • 2415.00
  • 2322.65
  • 2417.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 1424436
  • 33769.82
  • 3399.90
  • 1901.15

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 40,095.91
  • 33.26
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 44,627.91
  • 0.83%
  • 3.28

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.78%
  • 3.17%
  • 8.3%
  • FII
  • DII
  • Others
  • 0.27%
  • 11.47%
  • 50.01%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 17
Jun 16
Var%
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Sep 16
Sep 15
Var%
Net Sales
3,333.20
3,222.50
3.44%
3,611.90
3,756.20
-3.84%
3,723.20
3,967.90
-6.17%
3,616.30
3,988.96
-9.34%
Expenses
3,010.00
2,832.30
6.27%
3,021.40
3,279.70
-7.88%
2,858.70
3,222.30
-11.28%
2,989.30
3,095.17
-3.42%
EBITDA
323.20
390.20
-17.17%
590.50
476.50
23.92%
864.50
745.60
15.95%
627.00
893.79
-29.85%
EBIDTM
9.70%
12.11%
16.35%
12.69%
23.22%
18.79%
17.34%
22.41%
Other Income
38.00
67.00
-43.28%
20.50
30.70
-33.22%
40.30
12.20
230.33%
43.80
31.99
36.92%
Interest
21.50
14.80
45.27%
19.60
264.60
-92.59%
16.40
6.20
164.52%
12.60
21.64
-41.77%
Depreciation
259.20
243.60
6.40%
254.30
0.00
0.00
266.50
0.00
0.00
262.20
0.00
0.00
PBT
80.50
198.80
-59.51%
337.10
242.60
38.95%
621.90
751.60
-17.26%
396.00
904.14
-56.20%
Tax
23.70
52.60
-54.94%
9.70
173.90
-94.42%
138.50
178.80
-22.54%
95.60
187.88
-49.12%
PAT
56.80
146.20
-61.15%
327.40
68.70
376.56%
483.40
572.80
-15.61%
300.40
716.26
-58.06%
PATM
1.70%
4.54%
9.06%
1.83%
12.98%
14.44%
8.31%
17.96%
EPS
4.02
9.27
-56.63%
20.36
4.37
365.90%
29.69
33.95
-12.55%
18.63
42.32
-55.98%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
14,196.10
15,568.30
15,023.30
13,415.30
11,895.60
9,814.50
7,496.90
6,988.60
6,900.60
4,991.80
Net Sales Growth
-8.81%
3.63%
11.99%
12.78%
21.20%
30.91%
7.27%
1.28%
38.24%
 
Cost Of Goods Sold
3,444.90
3,758.50
3,786.40
3,317.10
3,516.80
2,568.30
2,091.10
2,061.70
1,940.40
1,601.20
Gross Profit
10,751.20
11,809.80
11,236.90
10,098.20
8,378.80
7,246.20
5,405.80
4,926.90
4,960.20
3,390.60
GP Margin
75.73%
75.86%
74.80%
75.27%
70.44%
73.83%
72.11%
70.50%
71.88%
67.92%
Total Expenditure
11,723.90
11,983.00
11,529.70
10,164.70
9,176.10
7,374.90
5,936.00
5,563.50
5,587.60
4,155.10
Power & Fuel Cost
330.10
315.20
339.10
319.90
335.40
225.90
183.30
141.50
122.70
97.60
% Of Sales
2.33%
2.02%
2.26%
2.38%
2.82%
2.30%
2.45%
2.02%
1.78%
1.96%
Employee Cost
3,106.80
3,117.40
2,944.60
2,475.40
1,928.70
1,591.20
1,304.80
1,183.20
992.00
731.00
% Of Sales
21.88%
20.02%
19.60%
18.45%
16.21%
16.21%
17.40%
16.93%
14.38%
14.64%
Manufacturing Exp.
2,138.20
1,856.40
1,999.10
1,747.60
1,441.30
1,237.00
985.90
921.80
1,115.30
768.40
% Of Sales
15.06%
11.92%
13.31%
13.03%
12.12%
12.60%
13.15%
13.19%
16.16%
15.39%
General & Admin Exp.
1,339.90
1,271.40
1,037.30
1,004.30
796.30
682.90
479.00
413.50
582.30
395.80
% Of Sales
9.44%
8.17%
6.90%
7.49%
6.69%
6.96%
6.39%
5.92%
8.44%
7.93%
Selling & Distn. Exp.
1,293.40
1,181.10
1,357.50
1,264.80
1,119.10
984.40
744.90
691.00
651.30
523.30
% Of Sales
9.11%
7.59%
9.04%
9.43%
9.41%
10.03%
9.94%
9.89%
9.44%
10.48%
Miscellaneous Exp.
70.60
483.00
65.70
35.60
38.50
85.20
147.00
150.80
183.60
523.30
% Of Sales
0.50%
3.10%
0.44%
0.27%
0.32%
0.87%
1.96%
2.16%
2.66%
0.76%
EBITDA
2,472.20
3,585.30
3,493.60
3,250.60
2,719.50
2,439.60
1,560.90
1,425.10
1,313.00
836.70
EBITDA Margin
17.41%
23.03%
23.25%
24.23%
22.86%
24.86%
20.82%
20.39%
19.03%
16.76%
Other Income
171.50
295.00
274.10
169.90
149.90
132.30
52.30
103.10
99.40
214.10
Interest
63.40
82.60
108.20
126.70
100.30
114.10
32.30
38.50
108.20
102.20
Depreciation
1,026.60
938.90
759.90
647.50
550.20
518.10
398.10
413.10
497.70
401.90
PBT
1,553.70
2,858.80
2,899.60
2,646.30
2,218.90
1,939.70
1,182.80
1,076.60
806.50
546.70
Tax
296.50
751.10
563.20
683.10
637.90
503.50
183.90
266.80
260.80
107.70
Tax Rate
19.08%
26.27%
19.42%
25.81%
29.47%
27.90%
15.55%
43.15%
-39.74%
19.70%
PAT
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
439.80
PAT before Minority Interest
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
439.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.80
PAT Margin
8.86%
13.54%
15.55%
14.63%
12.83%
13.25%
13.32%
5.03%
-13.29%
8.81%
PAT Growth
-40.35%
-9.79%
19.01%
28.58%
17.36%
30.23%
184.18%
138.33%
-308.53%
 
Unadjusted EPS
77.53
124.93
137.18
115.45
89.93
76.76
59.06
20.83
-54.48
26.07

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
12,262.10
12,569.80
9,853.10
7,865.20
6,369.10
4,989.00
4,031.90
3,776.80
3,526.10
4,496.90
Share Capital
82.90
85.30
85.20
85.10
84.90
84.80
84.60
84.40
84.20
84.10
Total Reserves
12,098.80
12,393.90
9,677.40
7,698.60
6,215.30
4,849.10
3,906.80
3,657.40
3,403.00
4,377.60
Non-Current Liabilities
456.10
876.70
1,678.40
2,182.30
1,285.10
1,609.80
600.30
1,491.00
2,051.40
2,049.00
Secured Loans
59.70
74.70
77.50
94.70
80.20
26.10
24.40
26.90
38.60
64.20
Unsecured Loans
485.20
993.80
1,354.00
1,980.80
1,185.70
1,615.80
512.80
1,457.10
1,959.00
1,904.20
Long Term Provisions
84.20
95.20
77.90
56.30
51.40
33.30
28.80
0.00
0.00
0.00
Current Liabilities
8,419.90
6,347.10
6,821.30
5,790.40
5,658.80
4,591.40
4,208.50
2,024.80
1,711.20
1,150.80
Trade Payables
1,056.90
906.80
867.30
893.20
965.70
756.60
634.50
1,667.90
1,505.60
1,027.50
Other Current Liabilities
2,339.70
2,409.10
2,624.40
2,020.80
2,120.40
1,749.20
1,328.90
6.70
6.20
5.80
Short Term Borrowings
4,362.60
2,271.80
2,185.70
2,060.70
1,898.60
1,588.80
1,831.90
0.00
0.00
0.00
Short Term Provisions
660.70
759.40
1,143.90
815.70
674.10
496.80
413.20
350.20
199.40
117.50
Total Liabilities
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70
7,696.70
Net Block
6,930.70
6,563.00
5,377.00
4,640.80
4,050.60
3,411.70
3,385.50
2,352.20
2,927.00
3,912.50
Gross Block
15,932.40
15,019.70
12,573.60
11,917.60
10,089.40
8,842.30
7,975.10
6,446.80
6,502.70
5,487.80
Accumulated Depreciation
8,961.40
8,456.70
7,169.90
7,276.80
5,984.60
5,295.30
4,589.60
4,094.60
2,112.90
1,575.30
Non Current Assets
11,454.40
7,999.60
6,476.10
5,512.20
4,786.30
4,191.20
4,025.70
3,115.00
3,357.20
4,312.20
Capital Work in Progress
3,324.50
772.20
529.00
638.80
565.30
708.50
575.20
762.20
429.60
268.40
Non Current Investment
682.60
329.70
145.60
0.40
0.40
0.90
0.90
0.60
0.60
131.30
Long Term Loans & Adv.
482.10
290.40
418.10
232.20
149.10
70.10
64.10
0.00
0.00
0.00
Other Non Current Assets
34.50
44.30
6.40
0.00
20.90
0.00
0.00
0.00
0.00
0.00
Current Assets
9,683.70
11,794.00
11,876.70
10,325.70
8,526.70
6,999.00
4,815.00
4,177.60
3,931.50
3,384.50
Current Investments
1,427.10
3,503.40
2,102.20
1,066.40
196.60
207.00
0.00
357.40
51.70
350.80
Inventories
2,852.80
2,557.90
2,569.90
2,418.80
2,170.70
1,943.30
1,599.20
1,339.40
1,325.00
1,101.90
Sundry Debtors
3,798.60
4,125.00
4,101.20
3,325.30
3,180.40
2,536.80
1,761.10
1,159.90
1,440.60
652.20
Cash & Bank
386.50
492.10
1,872.40
2,300.60
2,017.10
1,606.10
575.10
660.00
562.30
744.70
Other Current Assets
1,218.70
393.10
226.20
170.40
961.90
705.80
879.60
660.90
551.90
534.90
Short Term Loans & Adv.
767.20
722.50
1,004.80
1,044.20
796.90
611.60
763.20
658.70
551.20
532.10
Net Current Assets
1,263.80
5,446.90
5,055.40
4,535.30
2,867.90
2,407.60
606.50
2,152.80
2,220.30
2,233.70
Total Assets
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70
7,696.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
2,144.40
3,262.60
2,523.50
1,969.70
1,377.90
1,612.60
755.40
1,315.00
599.10
512.80
PBT
1,553.70
2,858.80
2,899.60
2,646.30
2,164.70
1,804.40
1,182.80
618.30
-656.30
545.00
Adjustment
1,692.70
1,107.70
1,654.00
1,042.70
1,062.80
1,157.40
530.10
1,117.30
2,080.10
523.40
Changes in Working Capital
-525.00
-2.50
-1,483.70
-1,005.00
-1,294.40
-893.80
-658.70
-137.50
-545.60
-402.40
Cash after chg. in Working capital
2,721.40
3,964.00
3,069.90
2,684.00
1,933.10
2,068.00
1,054.20
1,598.10
878.20
666.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-577.00
-701.40
-546.40
-714.30
-555.20
-455.40
-298.80
-283.10
-279.10
-153.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,840.40
-2,039.40
-2,264.70
-1,694.10
-1,446.30
-1,888.40
-898.80
-710.20
-505.00
-810.40
Net Fixed Assets
-1,019.30
-1,892.20
-828.10
-819.60
-530.80
-554.40
-399.90
-602.60
-571.80
-424.90
Net Investments
1,974.20
-1,213.80
-1,055.80
-427.30
98.50
-15.70
93.10
-851.30
226.80
-1,100.39
Others
-2,795.30
1,066.60
-380.80
-447.20
-1,014.00
-1,318.30
-592.00
743.70
-160.00
714.89
Cash from Financing Activity
-369.20
-1,700.10
-433.20
-24.20
-156.80
389.10
44.50
-531.70
-265.10
-775.40
Net Cash Inflow / Outflow
-65.20
-476.90
-174.40
251.40
-225.20
113.30
-98.90
73.10
-171.00
-1,073.00
Opening Cash & Equivalents
492.10
539.50
862.40
520.40
736.20
573.00
660.00
562.30
744.70
1,861.00
Closing Cash & Equivalent
377.80
492.10
582.90
862.40
520.40
736.20
575.10
660.00
562.30
744.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
734.72
731.49
572.92
457.33
371.04
290.91
235.90
221.67
207.08
265.26
ROA
6.14%
11.05%
13.67%
13.47%
12.46%
12.99%
12.38%
4.82%
-12.24%
5.70%
ROE
10.20%
18.95%
26.63%
27.88%
27.18%
29.15%
25.83%
9.72%
-23.07%
10.41%
ROCE
9.77%
19.55%
22.69%
24.77%
24.79%
26.24%
20.84%
12.18%
-9.14%
10.02%
Fixed Asset Turnover
0.92
1.13
1.23
1.23
1.26
1.17
1.04
1.09
1.16
0.99
Receivable days
101.86
96.43
89.72
87.97
87.19
79.59
70.77
67.20
55.01
51.82
Inventory Days
69.56
60.11
60.27
62.06
62.74
65.60
71.20
68.85
63.79
66.85
Payable days
31.00
28.67
28.48
33.96
34.99
35.37
72.19
108.29
85.61
85.15
Cash Conversion Cycle
140.42
127.87
121.51
116.06
114.93
109.82
69.78
27.76
33.19
33.52
Total Debt/Equity
0.40
0.27
0.44
0.58
0.58
0.66
0.59
0.40
0.57
0.44
Interest Cover
25.51
35.61
27.80
21.89
22.58
16.81
37.62
17.06
-5.07
6.35

News Update


  • USFDA completes audit at Dr. Reddy’s CPS facility in Telangana
    21st Sep 2017, 13:57 PM

    The USFDA has completed audit of said facility on September 21, 2017

    Read More
  • Dr. Reddy’s receives EIR from USFDA for Srikakulam Plant
    21st Sep 2017, 10:23 AM

    USFDA had recently completed the inspection at Dr. Reddy’s API Mirfield Plant, United Kingdom on September 15, 2017

    Read More
  • USFDA completes audit at Dr. Reddy’s API Mirfield plant in UK
    16th Sep 2017, 08:46 AM

    The company has been issued a Form 483 with three observations

    Read More
  • Dr. Reddy’s arm planning to initiate Phase 2 trial of CA-170
    13th Sep 2017, 08:51 AM

    CA-170 is an oral small molecule targeting the immune checkpoints PDL1 and VISTA

    Read More
  • German Regulatory issues zero critical, six major observations to Dr Reddy’s Duvvada facility
    8th Sep 2017, 11:14 AM

    Products manufactured at the facility are not currently exported to the EU

    Read More
  • Dr. Reddy’s Laboratories launches Metaxalone Tablets in US market
    6th Sep 2017, 11:44 AM

    The company’s Metaxalone Tablets, USP 800 mg are available in the bottle count size of 100

    Read More
  • Dr. Reddy's launches Bupropion Hydrochloride Extended-Release Tablets in US
    6th Sep 2017, 11:41 AM

    Dr. Reddy’s Bupropion Hydrochloride Tablets, 150 mg and 300 mg, are each available in bottle count sizes of 30, 90 and 500

    Read More
  • Dr. Reddy’s, Vivus settle long-pending patent litigation for Qsymia
    1st Sep 2017, 09:40 AM

    The settlement permits the Hyderabad-based drugmaker to begin selling a generic version of Qsymia from June 2025 or earlier under certain circumstances

    Read More
  • Dr. Reddy’s to reintroduce back pain-reliever Doan’s in US
    29th Aug 2017, 10:25 AM

    The company has launched a US marketing campaign to reintroduce Doan’s, available in caplets and a new 4% lidocaine plus menthol cream formulation

    Read More
  • Dr. Reddy’s faces class action suit in US District Court
    29th Aug 2017, 09:56 AM

    The lawsuit seeks damages to compensate the purported class of investors for a purported decline in the company’s share price

    Read More
  • Dr. Reddy’s Lab launches Cefixime for Oral Suspension in US markets
    28th Aug 2017, 11:25 AM

    The Suprax brand and generic had US sales of around $50.5 million MAT for the most recent twelve months ending in June 2017

    Read More
  • Dr. Reddy’s Laboratories out-license ‘DFD-06’ to Encore Dermatology
    22nd Aug 2017, 10:22 AM

    The drug is intended to be used for treatment of moderate to severe plaque psoriasis

    Read More
  • Dr. Reddy’s arm receives communication from Regulatory Authority of Germany
    10th Aug 2017, 15:10 PM

    The compnay has received a communication that the GMP compliance certificate in respect of the company's Formulations Manufacturing Unit 2 plant in Bachupally, Hyderabad is not renewed

    Read More
  • Dr. Reddy’s enters into global licensing agreement with CHD Bioscience
    27th Jul 2017, 16:25 PM

    The agreement is for the clinical development and commercialization of Dr. Reddy's phase III clinical trial candidate, DFA-02

    Read More
  • Dr. Reddys Lab - Quarterly Results
    27th Jul 2017, 12:00 AM

    Read More
  • USFDA completes audit at Dr. Reddy’s API Cuernavaca plant in Mexico
    21st Jul 2017, 11:09 AM

    The USFDA has completed the Audit for the same with Zero observation

    Read More
  • Dr. Reddy’s Laboratories launches Vozet Tablets in Indian market
    19th Jul 2017, 10:02 AM

    The drug is indicated for the treatment of allergic Rhinitis and chronic Urticaria

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.